Northwestern Mutual buys $12.5M CVS Health stake
What's the deal? Northwestern Mutual Wealth Management Co.Dealroom has a profile for this one. Try Dealroom → bought a new stake in CVS HealthDealroom has a profile for this one. Try Dealroom → worth roughly $12.47 million, according to its Q2 2026 filing with the US Securities and Exchange CommissionDealroom has a profile for this one. Try Dealroom →. The firm acquired 120,524 shares of the pharmacy operator in the second quarter.
Why now? The purchase follows a strong earnings report. On 5 August 2026, CVS posted quarterly revenue of $106.10 billion, up 7.3% year on year and above the $100.03 billion consensus estimate.
By the numbers: CVS reported earnings of $2.58 per share, beating the $1.87 estimate by $0.71. The company logged a net margin of 1.18% and a return on equity of 13.12%.
Northwestern Mutual was not alone. AllianceBernsteinDealroom has a profile for this one. Try Dealroom → raised its position by 8.0% to 1,609,404 shares worth $111 million, while Sei InvestmentsDealroom has a profile for this one. Try Dealroom → lifted its stake by 17.4% to 905,715 shares worth $62.47 million. Institutional investors and hedge funds own 80.66% of the company.
What the analysts say: CVS holds a consensus "Moderate Buy" rating and an average target price of $107.17, per MarketBeat. Of the analysts covering the stock, 22 rate it a Buy and two a Hold; Wells FargoDealroom has a profile for this one. Try Dealroom → raised its target to $123.
The state of play: On 21 August 2026, CVS opened at $93.01, below both its 50-day moving average of $102.02 and its 52-week high of $110.68. The company carried a market capitalisation of $118.96 billion and a P/E ratio of 24.61.
The signal: Steady institutional buying into a stock trading below recent highs points to confidence that CVS's revenue growth can outrun the pressures weighing on its share price.
Read more: Ticker Report
Image credit: Random Retail
